12064-010 : Benlysta 400 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: | 12064-010 |
Labeler: | Glaxosmithkline Manufacturing Spa |
Product Type: | Human Prescription Drug |
Drug Name: | Benlysta |
Dosage Form: | Intravenous Injection, Powder, Lyophilized, for Solution |
Application #: | BLA125370 |
Rev. Date: |
NDC Package Codes:
- 12064-010-00: 1 VIAL IN 1 CARTON (12064‑010‑00) > 5 ML IN 1 VIAL
Active Ingredients:
- Belimumab
Dosage Strength:
- 400 mg/5mL
Pharmaceutical Classes:
- Decreased B Lymphocyte Activation [PE]
- B Lymphocyte Stimulator-specific Inhibitor [EPC]
- B Lymphocyte Stimulator-directed Antibody Interactions [MoA]
Related Products:
Based on records with the same trade name.- 12064-009 Benlysta 120 mg/1.5ml Intravenous Injection, Powder, Lyophilized, for Solution by Glaxosmithkline Manufacturing Spa
- 49401-088 Benlysta 200 mg/ml Subcutaneous Solution by Human Genome Sciences, Inc.
- 49401-101 Benlysta 120 mg/1.5ml Intravenous Injection, Powder, Lyophilized, for Solution by Human Genome Sciences, Inc.
- 49401-102 Benlysta 400 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Human Genome Sciences, Inc.
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 12064-009Next: 12064-011 >
Related Discussions:
Migraines associated to Benlysta use?
I am going for my fourth Benlysta treatment tomorrow and although I've noticed huge differences in my mobility and j... 10 replies
I am going for my fourth Benlysta treatment tomorrow and although I've noticed huge differences in my mobility and j... 10 replies
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.